Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series

Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series

Abstract Three patients diagnosed with severe COVID‐19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and...

Full description

Bibliographic Details
Main Authors: Manoon Surabotsophon, Yingyot Klai‐On, Vipa Thanachartwet, Sirote Khunapornphairote, Supat Chamnanchanunt, Theerapat Racharak, Wannada Laisuan, Duangjai Sahassananda, Samlee Hapunna, Somjit Jinapuk, Suthee Leelasetakul, Varunee Desakorn
Format: Article
Language:English
Published: Wiley 2020-12-01
Series:Clinical Case Reports
Subjects:
COVID‐19
pneumonia
acute respiratory distress syndrome
tocilizumab
Online Access:https://doi.org/10.1002/ccr3.3407

Internet

https://doi.org/10.1002/ccr3.3407

Similar Items